The Effects of PLGA Nanoparticles Containing Different Growth Factors on Neural Stem Cell Differentiation and Their Transition Efficiency After Targeting With TRF
Open Access
- 4 September 2025
- journal article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (9) , e70576
Abstract
Aims: Nanoparticle‐mediated drug delivery systems are being investigated for the controlled release of drugs to treat neurodegenerative diseases (ND). We aimed to investigate the effects of poly(lactic‐co‐glycolic acid) nanoparticles (PLGA‐NPs) containing different growth factors (GFs) on rat brain‐derived neural stem cells (NSCs) in vitro differentiation, providing insights that may contribute to future approaches for treating Parkinson's disease.Methods: Three different PLGA‐NPs loaded with Brain‐Derived Neurotrophic Factor (BDNF), Glial‐Derived Neurotrophic Factor (GDNF), and Transforming Growth Factor beta 3 (TGF‐β3) were developed and characterized in terms of size, zeta potential, encapsulation efficiency, and release profile. These NPs were used to differentiate NSCs into dopaminergic neurons in vitro. Additionally, the transition of transferrin (TRF)‐conjugated PLGA‐COOH‐NPs across an in vitro blood–brain barrier (BBB) model was investigated.Results: The average sizes of BDNF, GDNF, and TGF‐ß3 loaded PLGA‐NPs were measured to be 217.17 ± 1.37, 227.37 ± 5.39, and 220.57 ± 10.10 nm, respectively. Besides, SEM imaging revealed that the particles had a homogeneous size distribution and smooth surface morphology. Microtubule‐associated protein 2 (Map2) and tyrosine hydroxylase (TH), two dopaminergic neuronal markers, were found in cells with neuron‐like morphology that were produced through in vitro differentiation. The cellular uptake of PLGA‐NPs loaded with Coumarin‐6 was determined by using confocal imaging and flow cytometry. It was demonstrated that TRF‐conjugated NPs were specifically targeted and taken up into NSCs in the in vitro BBB model.Conclusion: It is concluded that BDNF‐PLGA‐NPs, GDNF‐PLGA‐NPs, and TGF‐ß3‐PLGA‐NPs are promising brain drug delivery carriers for NSC inducers, which could be useful in developing strategies for Parkinson's disease management, particularly when targeted with TRF.Keywords
This publication has 52 references indexed in Scilit:
- The Story of Nanoparticles in Differentiation of Stem Cells into Neural CellsNeurochemical Research, 2019
- Nanoparticle technology and stem cell therapy team up against neurodegenerative disordersAdvanced Drug Delivery Reviews, 2019
- Neural Stem Cell-Based Therapeutic Approaches for Brain Repair2018
- Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatmentColloids and Surfaces B: Biointerfaces, 2016
- Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseasesJournal of Controlled Release, 2016
- In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s diseaseEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's diseaseMovement Disorders, 2011
- Medial Ganglionic Eminence-Derived Neural Stem Cell Grafts Ease Spontaneous Seizures and Restore GDNF Expression in a Rat Model of Chronic Temporal Lobe EpilepsyStem Cells, 2010
- LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumorsInternational Journal of Pharmaceutics, 2010
- Behavior of hippocampal stem/progenitor cells following grafting into the injured aged hippocampusJournal of Neuroscience Research, 2008